Evidence map›Paper›PMID 35118822›Full record

ReviewESC heart failure2022

Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction.

Magdy Abdelhamid, Hossam Kandil, Mahmoud Hassanin, Sameh Shaheen, Mohamed Sobhy, Adel ElEtreby, Hosam Hasan-Ali, Hala Mahfouz, Gamila Nasr, Islam Shawky and 9 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 2 countries.

Magdy AbdelhamidFaculty of Medicine, Kasr Al Ainy, Cardiology Department, Cairo University, Cairo, Egypt.ORCID 0000-0002-6701-7072
Hossam KandilFaculty of Medicine, Kasr Al Ainy, Cardiology Department, Cairo University, Cairo, Egypt.
Mahmoud HassaninFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Sameh ShaheenFaculty of Medicine, Ain Shams University, Cairo, Egypt.
Mohamed SobhyFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Adel ElEtrebyFaculty of Medicine, Ain Shams University, Cairo, Egypt.
Hosam Hasan-AliFaculty of Medicine, Assiut University, Asyut, Egypt.
Hala MahfouzFaculty of Medicine, Menoufia University, Shibin Al Kawm, Egypt.
Gamila NasrFaculty of Medicine, Suiz Canal University, Ismailia, Egypt.
Islam ShawkyFaculty of Medicine, Al Azhar University, Cairo, Egypt.
Sameh EmilArmed Forces College of Medicine, Cardiology Department, Cairo, Egypt.
Mohamed ElSetihaFaculty of Medicine, Tanta University, Tanta, Egypt.
Mohamed HasssanFaculty of Medicine, Kasr Al Ainy, Cardiology Department, Cairo University, Cairo, Egypt.
Yasser SadekFaculty of Medicine, Helwan University, Helwan, Egypt.
Mohamed Abdelghany KarimFaculty of Medicine, Assiut University, Asyut, Egypt.
Ayman AshamFaculty of Medicine, Aswan University, Aswan, Egypt.
Mohamed GhalebCardiology Unit, Research Institute of Ophthalmology, Cairo, Egypt.
Ahmad SamirFaculty of Medicine, Kasr Al Ainy, Cardiology Department, Cairo University, Cairo, Egypt.
Khaled ShokryArmed Forces College of Medicine, Cardiology Department, Cairo, Egypt.
Cairo University · EGAin Shams University · EGAlexandria University · EGArmed Forces College of Medicine · EGAssiut University · EGAl-Azhar University · EGAswan University · EGHelwan University · EGMenoufia University Hospitals · EGResearch Institute of Ophthalmology · EGSuez Canal University · EGTanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium-glucose cotransporter-2 inhibitor (SGLT2i) in patients with type 2 diabetes reduces the risk of serious heart failure events, specifically the risk of hospitalization for heart failure, and cardiovascular death. The benefit is most apparent in patients with a heart failure with reduced ejection fraction (HFrEF). Dapagliflozin and empagliflozin reduced the risk of cardiovascular death and hospitalizations for heart failure in patients with established HFrEF, including those without diabetes. Considering the magnitude of the problem and the expected benefit on the target population, an Egyptian consensus document was conducted to demonstrate the importance of and the critical knowledge needed for effective and safe implementation of SGLT2i in the daily practice for the management of patients with HFrEF.

Indexed as

Diabetes Mellitus, Type 2Heart FailureSodium-Glucose Transporter 2 InhibitorsEgyptGlucoseHumansSodiumStroke VolumeGlucoseSodiumSodium-Glucose Transporter 2 InhibitorsHeart failure with reduced ejection fractionSodium-glucose cotransporter-2 inhibitor

Identifiers

PMID35118822
PMCPMC8934981
OpenAlexW4210427521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.